PhorMed on StartEngine

Utilizing gene therapy to target cancer and mutated cells

Raise to date: $126,700

Reporting Date: 01/22/2020

Key Stats

Minimum Raise

$10,000

Maximum Raise

$107,000

Likelihood of Max Exceeded
Start Date

12/06/2019

Stop Date

03/12/2020

Days Remaining

49

Security Type

Common Stock

Investment Minimum

$250

Deal Type

No Review


Investment Summary

Status

Active

# of Investors

261

% of Minimum Raised

1,267%

% of Maximum Raised

118%

Dollars Per Day to Reach Max

N/A

DPD* Committed

$2,696

DPD* Category

$0

DPD* All Companies

$1,131

Kingscrowd Momentum

$126,700

Total Dollars Raised

Commitments

Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

PhorMed, with a pre-money valuation of $39 million, is raising funds on StartEngine.It is a biopharmaceutical company that is changing the face of genomic medicine. PhorMed uses gene therapy to target and treat cancer cells and mutated cells, and develops a treatment for patients suffering from Hodgkin’s Lymphoma, Parkinson’s Disease, and Acute Myeloid Leukemia. PhorMed was founded by McCoy Moretz Richard L. Chang and others. The proceeds of the current crowdfunding round, with a minimum target of $10,000 and a maximum target of $107,000, will be used for the Phase 2 clinical trials of the drug. PhorMed uses a leading technology, RP-323, as its gene repair therapy. The drug has completed Phase 1 of the clinical study and has generated positive outcomes.

INVEST NOW